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Abstract The expression of CYP1B1 has been identified in 
breast cancer using the reverse transcriptase-polymerase chain 
reaction and immunoblotting. CYP1B1 mRNA was expressed in 
the majority of breast tumours and immunoblotting of breast 
tumours identified a single protein band of molecular weight 60 
kDa corresponding to the predicted molecular weight of human 
CYP1B1. This is the first study to identify CYP1B1 expression 
in a turnout where it may represent a previously unknown path- 
way for the metabolism of oestradiol and chemotherapeutic 
drugs. 
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1. Introduction 
The P450s are a multigene superfamily of constitutive and 
inducible enzymes which play a central role in the oxidative 
metabolism of a diverse range of xenobiotics, including carcin- 
ogens, therapeutic drugs and several groups of biologically 
active endogenous compounds, such as steroid hormones and 
fatty acids [1-5]. The major families of P450 involved in xeno- 
biotic metabolism each consist of several individual forms with 
specific regulatory mechanisms and substrate specificities [6]. 
Until recently, the CYP1 gene family which is the main P450 
family involved in the metabolism of polycyclic aromatic om- 
pounds and arylamines and is regulated by the Ah receptor 
complex, was considered to be composed of only two distinct 
but closely homologous members, CYP1A1 and CYP1A2 
[7-10]. In man, CYP1A1 is an inducible P450 found primarily 
in extrahepatic tissues while CYP1A2 is constitutively ex- 
pressed in liver [11]. Recently, a new dioxin-inducible CYP1 
P450 subfamily has been identified, containing one form to 
date, CYP1B1 [12]. Using immunohistochemistry, we have pre- 
viously identified a CYPl- immunoreactive protein in breast 
cancer [13] and in this study we have investigated the expression 
of individual forms of the two known CYP1 gene subfamilies 
in breast cancer. 
2. Materials and methods 
2.1. Tumour samples 
Samples of breast tissue were obtained from patients undergoing 
surgery for primary breast cancer. In accordance with current pathol- 
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Abbreviations: P450, cytochrome P450; RT-PCR, reverse transcriptase- 
polymerase chain reaction. 
ogy guidelines requiring the majority of each breast biopsy to be sub- 
mitted for histopathological examination, only small samples were 
available for this study and were, therefore, used either for RT-PCR 
or immunoblotting. RT-PCR was performed on breast cancers from 42 
patients (age range 33-87). Immunoblotting was performed on breast 
cancers obtained from 6 patients (age range 45 67). The tissue samples 
were frozen in liquid nitrogen and stored at -80°C prior to analysis. 
2.2. RT-PCR 
Total RNA was extracted using essentially the method of 
Chomczynski and Sacchi [14]. The recovered RNA pellet was washed 
twice with 95% ethanol before being air-dried and resuspended in 20/11 
diethyl pyrocarbonate (Sigma, Poole, UK)-treated distilled water. 
cDNA was synthesized from the isolated RNA using oligo (dT) with 
the following reaction conditions: RNA (20/11) in 50 mM Tris-HC1, pH 
8.3, 50 mM KCI, 10 mM MgCI2, 0.5 mM spermidine, 10 mM dithiothre- 
itol, 40 U human placental ribonuclease inhibitor (Promega, 
Southampton, UK), 0.125 mM each of dATR dCTP, dGTP and dTTP 
(Promega), 18 U avian myeloblastosis virus reverse transcriptase 
(Promega) and 0.5 mg oligo (dT)~5 primer (Promega). cDNA was then 
synthesized at 42°C for 60 min and the reaction was stopped by heating 
to 80°C for 5 min. 
The CYP1B1 primers recognize sequences in the 3' non-coding re- 
gion of the CYP1B1 gene and give a product of 489 bp [12]. The CYP1A 
primers were designed to recognize sequences common to both 
CYP1A1 and CYP1A2 and give PCR products of 649 bp for CYP1A1 
and 643 bp for CYP1A2, respectively. Each product contained an RsaI 
restriction site (corresponding to nt 1102 for CYP1A1 and nt 1002 for 
CYP1A2, respectively [7,9]) and gave fragments of 535 and 114 bp for 
CYP1A1 and 507 and 136 bp for CYP1A2, respectively. The primers 
were synthesized and purified using high-performance liquid chroma- 
tography by Oswel DNA Service (Edinburgh, UK) with the following 
sequences: 
CYP1BI 
Forward 
Reverse 
CYP1A 
Forward 
Reverse 
5 ' -AAC TGT CCA TCA GGT GAG GT-3'  (nt 2104-2123)  
5 ' -TAAGGA AGT ATA CCA GAAGGC-3 '  (nt 2573-2593)  
5 ' -GAG CAT GTG AGCAAG GAG G-3' (CYPIAI,  nt 567-585;  
CYPIA2,  nt 495-513)  
5 ' -CGGAAG GTC TCC AGG ATGAA-3 '  (CYPIAI, nt 1197-  
1216; CYPIA2,  nt  1119-1138)  
fl-Actin primers were bought from Stratagene (Cambridge, UK) and 
had the following sequences: 
Forward 5 ' -TGA CGG GGT CAC CCA CAC TGT-GCC CAT CTA-3'  (nt 
1038-1067)  
Reverse 5 ' -CTA GAA GCA TTT  GCG GTG GAC GAT GGA GGG-3  ' (nt 1876-  
1905) 
PCR using the hot-start echnique [15] was performed in a 100-BI 
reaction volume consisting of 10 mM Tris-HC1, pH 9.0, 50 mM KC1, 
0.1% Triton X-100, either 1.5 mM MgC12 (for CYP1B1) or 2.5 mM 
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MgCI2 (for CYP1A), 0.2 mM (CYP1B1) or 0.4 mM (CYP1A) each of 
dATE dCTP, dGTP and dTTP, 0.5 U Taq DNA polymerase 
(Promega), 2/11 cDNA and either 100 pmol of each primer for both 
CYP1B1 and fl-actin or 85 pmol of each CYP1A primer. 35 cycles of 
amplification were performed using the following conditions: for 
CYP1BI: 94°C for 30 s (denaturation), 60°C for 30 s (annealing), 72°C 
for 1 min (extension); and a final 2-min extension at 72°C; for CYP1A: 
94°C for 1.3 min (denaturation), 55°C for 36 s (annealing), 72°C for 
1.3 min (extension) and a final 2-min extension at 72°C. For fl-actin, 
the conditions were (as recommended by the manufacturer's data 
sheet): denaturation at 94°C for 5 min, annealing at 60°C for 5 min 
followed by 35 cycles of amplification consisting of 94°C for 48 s 
(denaturation), 60°C for 48 s (annealing), 72°C for 1.5 min (extension) 
and a final extension at 72°C for 10 min. Both positive and negative 
controls were included in the PCR. The positive control for CYP1BI 
was a 2.78-kb CYP1B1 cDNA which had been cloned into pcDNAII. 
Positive controls used for CYP1A were cloned full-length human 
CYP1A1 and CYP1A2 cDNA sequences which were kindly provided 
by Professor D.W. Nebert (University of Cincinnati, USA). The nega- 
tive control was sterile distilled water in place of template cDNA. Both 
the fl-actin primers and CYP1A primers pan intron sequences and the 
absence of any band at a higher molecular weight han expected from 
the cDNA confirms absence of contaminating DNA in the RNA prep- 
arations. 
After PCR, 10/21 of the PCR product was electrophoresed on a 1.5% 
agarose gel which incorporated 0.007% w/v ethidium bromide. The 
PCR product was purified with a Wizard miniprep DNA purification 
system (Promega) used according to the manufacturer's instructions 
and further analysed by direct sequencing (CYP1B1 and CYP1A) and 
restriction enzyme digestion with RsaI (CYP1A) as follows. The 
CYP1BI and CYPIA PCR products were sequenced by the direct 
dideoxy sequencing technique of Sanger [16] with a T7 sequencing kit 
(Pharmacia, Milton Keynes, UK) used according to the manufacturer's 
protocol. The sequencing primers were the same primers used for PCR. 
Purified CYP1A PCR product was also digested with RsaI for 2 h at 
37°C with the following conditions: 25/21 DNA in 10 mM Tris-HC1 pH 
7.9, 50 mM NaC1, 10 mM MgC12, 1 mM dithiothreitol, 20 mg bovine 
serum albumin (Sigma) and 0.02 U RsaI (Promega), then heated to 
95°C for 2 min to stop the reaction. Restriction digests were analysed 
by electrophoresis on an ethidium bromide-containing agarose gel as 
above. 
2.3. Immunoblotting 
Sodium dodecyl sulphate polyacrylamide g l electrophoresis and im- 
munoblotting ofbreast umours using an enhanced chemiluminescence 
technique to identify immunoreactive proteins were performed as de- 
scribed previously [17,18]. 
3. Results 
3.1. RT-PCR 
Of the 42 tumours studied by RT-PCR, 40 of the tumours 
amplified for fl-actin and the 2 tumours which did not amplify 
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489bp 
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Fig. 2. Ethidium bromide stained agarose gel of breast umours follow- 
ing PCR with CYP1A primers. Lanes 1 and 11, molecular weight 
markers (2HindIII fragments); lanes 2-7, breast umours; lane 8, nega- 
tive control (water); lanes 9 and 10, positive controls (CYP1A1 and 
CYPIA2 plasmids, respectively). 
for fl-actin are not considered further. 29 of the 40 tumours 
(73%) amplified for CYP1B1 (Fig. 1) and sequencing of the 
purified PCR product showed identity with CYP1B1. RT-PCR 
for CYP1A showed that 10 of the 40 tumours (25%) amplified 
for CYP1A (Fig. 2) and direct sequencing of the undigested 
CYP1A PCR product showed identity with CYP1A1. Follow- 
ing digestion of the PCR product with RsaI, two bands of 535 
and 114 bp, respectively, were identified, consistent with the 
digestion products of CYP1A1 (Fig. 3). None of the tumours, 
however, showed evidence of expression of CYP1A2 mRNA 
(Fig. 3). There was only 1 tumour which expressed CYP1A1 
without co-expressing CYP1B1 mRNA while 10 of the tumours 
showed no amplif ication for either CYP1B1 or CYP1A1. 
3.2. Immunoblotting 
Although CYP1B1 mRNA has previously been identified by 
Northern blott ing in several normal human tissues [12] to date 
the presence of CYP1B1 protein has not been demonstrated. 
Immunoblott ing of breast tumours was performed using an 
anti-CYP1 ant ibody which we have shown to recognize human 
CYP1B1 expressed in E. coll. All of the breast tumours exam- 
ined showed a single immunoreact ive band at 60 kDa (Fig. 4) 
corresponding to the predicted molecular weight of human 
CYP1BI.  
1 2 3 4 5 6 7 8 9 
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Fig. 1. Ethidium bromide stained agarose gel of CYP1B 1 breast umour 
PCR product. Lanes 1 and 10, molecular weight markers (2HindlII 
fragments); lanes 2-7, breast umours; lane 8, negative control (water); 
lane 9, positive control (CYP1BI cDNA). 
Fig. 3. Ethidium bromide stained agarose gel of CYP 1A PCR products 
following RsaI digestion. Lanes 1 and 9, molecular weight markers 
(100-bp ladder); lanes 2-6, breast tumours; lanes 7 and 8, positive 
controls (CYP1A1 and CYP1A2 plasmids, respectively). 
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Fig. 4. Immunoblot of breast tumours showing an immunoreactive 
band at 60 kDa. Lanes 1 6, breast umours. 
4. Discussion 
The expression of individual forms of the CYP1 gene family 
in breast cancer has been investigated. It had been widely 
thought hat the CYP1 gene family consisted of only one sub- 
family, containing two highly homologous members, CYPI A1 
and CYP1A2. Recently, however, a new member of the CYP1 
family, CYP1B1, belonging to a new subfamily, was identified 
in dioxin-induced human keratinocytes and showed -40% iden- 
tity with both CYP1A1 and CYP1A2 [12]. In the current study, 
both CYP1A1 and CYP1B1 mRNA were shown to be ex- 
pressed in breast tumours, with CYP1B1 mRNA being the 
most frequently expressed. CYP1A2 mRNA was not identified 
in any of the tumours. 
The strategy we used for identifying individual members of 
the CYP1A subfamily was to use primers which recognize se- 
quences common to both CYP1A1 and CYP1A2, followed by 
RsaI restriction enzyme digestion to give different pairs of frag- 
ments for CYP1A1 and CYP1A2, respectively, with sizes that 
allowed their resolution on agarose gel electrophoresis. These 
results were confirmed by direct dideoxy sequencing of the 
undigested PCR product. 
Both CYP1A1 and CYP1B1 have been shown to be regu- 
lated by compounds which act at the Ah receptor [8,12]. How- 
ever, this study clearly shows differential expression of 
CYP1A1 and CYP1B1, with CYP1B1 being the most fre- 
quently expressed member of the CYP1 gene family in breast 
cancer. 
The expression of CYP1B1 in breast cancer is likely to have 
important metabolic consequences for the tumour cells, e.g. 
with respect to oestrogen metabolism as breast cancer is an 
oestrogen-dependent tumour. Dioxin induction of MCF-7 
breast cancer cells resulted in marked NADPH-dependent 
4-hydroxylation of 17fl-oestradiol which was not inhibited by 
an anti-CYP1A1 antibody [18] and was inhibited by an anti- 
body raised against mouse P450EF [19], now identified as 
murine CYP1B 1 [20], suggesting that CYP1B 1 may contribute 
to the 4-hydroxylation of oestradiol. 
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